Drugs / RO7656594
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05800665 | May 2023 → Jun 2027 expected | metastatic prostate carcinoma | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7656594 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800665 ↗ |
| Route | Oral | “RO7656594 will be administered orally at specified dose on specified days.” NCT05800665 ↗ |